World J Gastroenterol. 2010 Mar 28;16(12):1427-9. doi: 10.3748/wjg.v16.i12.1427.
It is common practice to follow patients with colorectal cancer for some years after resection and/or adjuvant treatment. Data are lacking about how often patients should be seen, what tests should be performed, and what surveillance strategy has a significant impact on patient outcome. Seven randomized trials have addressed this issue, but none had sufficient statistical power. Four published meta-analyses have established that overall survival is significantly improved for patients in the more intensive programs of follow-up. This improvement amounts to a risk difference of 7% (95% CI: 3%-12%, P = 0.002) in 5-year survival. This should be partly attributable to more frequent reoperation for cure of asymptomatic recurrence, or more intense follow-up, as well other factors, such increased psychosocial support and well-being, diet and lifestyle optimization, and/or improved treatment of coincidental diseases. A large-scale multicenter European study [Gruppo Italiano di Lavoro per la Diagnosi Anticipata (GILDA)] is underway to answer the question of what constitutes optimal surveillance for patients after primary therapy, based on an adequately powered study.
对结直肠癌患者进行切除和/或辅助治疗后,通常会进行数年的随访。目前还缺乏关于患者应多久就诊、应进行哪些检查以及哪种监测策略对患者预后有显著影响的数据。有 7 项随机试验已经解决了这个问题,但没有一项具有足够的统计学效力。4 项已发表的荟萃分析已经证实,对于接受更密集随访方案的患者,总体生存率显著提高。在 5 年生存率方面,这种改善相当于风险差异为 7%(95%CI:3%-12%,P=0.002)。这部分归因于更频繁地进行无症状复发的根治性手术,或更密集的随访,以及其他因素,如增加社会心理支持和幸福感、优化饮食和生活方式,以及/或更好地治疗偶发疾病。一项大型多中心欧洲研究[意大利早期诊断工作组(GILDA)]正在进行中,旨在根据一项充分有力的研究,回答什么是原发性治疗后患者最佳监测的问题。